Abstract:Abstract Regulatory T (Treg) cells play an important role in modulating the tumor microenvironment, leading to the suppression of anti-tumor immune responses. Tumor Tregs could be targeted by taking advantage of the differential expression of immune checkpoints on these cells as compared to other T cell subsets. While the elevated expression of checkpoints such as CTLA-4 on Tregs compared to conventional T cells is well-characterized, less is known about the collective landscape of Treg specific checkpoint expression specific in the tumor microenvironment. We identified a network of Treg-associated checkpoint markers including those previously associated with Treg function (CTLA4, ICOS) as well as several additional checkpoints (BTLA, LAG3, TIGIT, TNFRSF9) by characterizing the expression of 28 checkpoint molecules across 7,608 bulk tumor samples (31 tumor types) from TCGA. We then utilized whole transcriptome RNA sequencing of purified peripheral and tumor Treg cell populations across 4 different tumor types (glioblastoma multiforme, prostatic adenocarcinoma, urothelial transitional cell carcinoma, renal clear cell carcinoma) to characterize the Treg specific expression of checkpoint molecules. Peripheral and tumor Tregs demonstrate differential checkpoint expression landscapes, with tumor Tregs uniquely discriminated by collective expression of TNFRSF9 (4-1BB), HAVCR-2 (TIM-3), and LAG-3. This discriminatory signature was conserved across the 4 profiled tumor types, was associated with changes in Treg biology, and was confirmed in published data from three additional cancer cohorts (breast, colorectal, and non-small-cell-lung cancers). Furthermore, normalized TNFRSF9 expression in TCGA was also associated with a worse survival outcome, suggesting that elevated Treg TNFRSF9 expression may be a poor prognostic factor across a wide range of tumors. Taken together, these data highlight the potential of targeting TNFRSF9 expressing Tregs in the tumor as a novel immunotherapeutic approach for several types of cancer. Citation Format: Zachary T. Freeman, Daniel H. Hovleson, Alexander T. Pearson, Jingyi Zhai, Ali Ghasemzadeh, Thomas R. Nirschl, Hui Jiang, Scott A. Tomlins, Charles G. Drake. A conserved checkpoint molecule signature offers novel targets for tumor specific regulatory T cell manipulation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-118.

RNA-Binding Protein PCBP1/hnRNP E1 is an Intracellular Checkpoint for Shaping Effector Versus Regulatory T Cells in Immunity and Cancer

RNA binding protein PCBP1 is an intracellular immune checkpoint for shaping T cell responses in cancer immunity

RNA-binding Protein PCBP1 Shapes Tolerance and Immune Response by Constraining the Formation of Regulatory T Cells

Tumor Immune Checkpoints and Their Associated Inhibitors

Protein Phosphatase 2a (Pp2a) Is Essential For Cd8+T Cell Mediated Anti-Tumor Immunity

The RNA-binding protein PCBP1 represses lung adenocarcinoma progression by stabilizing DKK1 mRNA and subsequently downregulating β-catenin

The ITPRIPL1- CD3ε Axis: a Novel Immune Checkpoint Controlling T Cells Activation

PD-1 protects expanding human T cells from premature restimulation-induced cell death.

Time-dependent regulation of cytokine production by RNA binding proteins defines T cell effector function

Polypyrimidine tract binding protein 1 regulates the activation of mouse CD8 T cells

Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells

PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

Regulatory T cells in immune checkpoint blockade antitumor therapy

Targeting TNFR2 to overcome acquired adaptive resistance to immune checkpoint blockade

PD1 inhibits PKCθ-dependent phosphorylation of cytoskeleton-related proteins and immune synapse formation

Abstract LB-118: A Conserved Checkpoint Molecule Signature Offers Novel Targets for Tumor Specific Regulatory T Cell Manipulation

The Phosphatase PAC1 Acts As a T Cell Suppressor and Attenuates Host Antitumor Immunity

CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer